3D1015 / 3DMed - LARVOL DELTA

Development and evaluation of a novel high affinity PSMA-targeted radioligand177Lu-PSMA-3D1015 for prostate cancer (AACR 2026) - "Background: The clinical efficacy of PSMA targeted RLT for metastatic PCa has been well established by Pluvicto®. 177Lu-PSMA-3D1015 exhibits high PSMA affinity and prolonged retention in tumor, potentially driving potent efficacy at lower doses. Its distinct hepatobiliary excretion profile differentiates it from existing therapies. These findings address key limitations of current RLTs, and further clinical trials are ongoing."

Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

SUCCESSFULLY ADMINISTERS FIRST DOSE IN HUMAN FOR NOVEL RADIOACTIVE DRUG CONJUGATE 3D1015 (HKEXnews) - "The study aims to evaluate the safety and preliminary efficacy of 3D1015 in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC)."

Trial status • Castration-Resistant Prostate Cancer